miR-574-3p正反馈调控HIF/VEGF血管生成通路的分子机制研究
结题报告
批准号:
31571443
项目类别:
面上项目
资助金额:
60.0 万元
负责人:
杨青
依托单位:
学科分类:
C0702.细胞信号转导
结题年份:
2019
批准年份:
2015
项目状态:
已结题
项目参与者:
曹宏、薛辉、何海涛、张仁文、徐阳、丁蕾、睢朋成、吉璐
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
客服二维码
微信扫码咨询
中文摘要
细胞通过HIF/VEGF通路促进周边血管生成,该通路调控机理尚未完全阐明。我们前期发现miR-574-3p上调VEGF表达,下调HIF对抗因子CUL2表达;缺氧升高细胞中HIF-1α蛋白含量、上调miR-574-3p表达、下调CUL2表达。本项目中我们拟阐明:1)CUL2是miR-574-3p的靶基因;2)miR-574-3p通过抑制CUL2抑制细胞内E3-泛素连接酶复合物的形成,解除后者介导的HIF-1α降解,激活HIF/VEGF通路,促进细胞外血管生成;3)HIF-1α上调miR-574-3p的表达,后者通过抑制CUL2进一步加强HIF/VEGF通路的活性,对缺氧诱发的细胞外血管生成形成正反馈调控作用。本项目的完成将阐明细胞内miR-574-3p促进细胞周围血管生成的分子通路及调控机制,对血管生长和发育、组织创伤愈合、心脑血管阻塞后血管再生、肿瘤组织血管生成等具有普遍的理论和实践意义。
英文摘要
Cells can promote extracellular angiogenesis through an intracellular HIF / VEGF pathway, but the regulatory mechanism of this pathway has not been fully elucidated. Our previous work found that miR-574-3p induced up-regulation of vascular endothelial growth factor (VEGF) mRNA expression and down-regulation of mRNA and protein expression of cullin 2, an antagonist of hypoxia-inducible factor (HIF) ; Hypoxia increased intracellular HIF-1α protein content,upregulated miR-574-3p expression and downregulated cullin2 mRNA expression. In this project, we intend to prove that: 1) cullin 2 mRNA is a direct target of miR-574-3p; 2)miR-574-p inhibits the formation of E3 ubiquitin ligase complex through down-regulation of cullin 2, elevating intracellular HIF by inhibiting its degradation and activating the HIF/VEGF pathway to promote extracellular angiogenesis; 3) up-regulation of HIF by hypoxia promotes miR-574-3p expression which further increases activity of the HIF/VEGF pathway through an inhibition of cullin2 mRNA playing a role in positive feedback of hypoxia-induced extracellular angiogenesis. The completion of this project will elucidate the intracellular molecular pathway and regulatory mechanism of extracellular angiogenesis via miR-574-3p. We believe that further understanding of this pathway and regulatory mechanism would have significant practical and theoretical implications for angiogenesis-associated physiological or pathological processes such as in growth and development of blood vessel, wound healing, tumor development and cardio/cerebral vascular occlusion.
细胞通过HIF/VEGF通路以旁分泌的方式促进细胞周围血管生成,该通路调控机理尚未完全阐明。MicroRNA是新近发现的一类重要的转录后调控因子,广泛参与了机体的生理和病理过程,包括血管生成。在本项目研究中,我们阐明了胃癌细胞中miR-574-3p正反馈调控HIF/VEGF血管生成通路的分子机制。我们的研究结果表明,缺氧条件下,胃癌细胞HIF-1α蛋白的水平升高,HIF-1α蛋白能够直接启动miR-574基因的转录,提高细胞中miR-574-3p的水平。MiR-574-3p通过直接抑制胃癌细胞中CUL2蛋白的表达,并由此抑制细胞中HIF-1α蛋白的泛素化降解过程,从而稳定细胞中HIF-1α蛋白水平,然后通过HIF/VEGF通路促进血管的生成。本项目研究不仅丰富了血管生成调控机制的理论,也为通过阻断血管生成从而治疗肿瘤提供了潜在的靶点。
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
Oxaloacetate Ameliorates Chemical Liver Injury via Oxidative Stress Reduction and Enhancement of Bioenergetic Fluxes.
草酰乙酸通过减少氧化应激和增强生物能通量来改善化学性肝损伤
DOI:10.3390/ijms19061626
发表时间:2018-05-31
期刊:International journal of molecular sciences
影响因子:5.6
作者:Kuang Y;Han X;Xu M;Wang Y;Zhao Y;Yang Q
通讯作者:Yang Q
Biomarker and competing endogenous RNA potential of tumor-specific long noncoding RNA in chromophobe renal cell carcinoma.
嫌色肾细胞癌中肿瘤特异性长非编码RNA的生物标志物和竞争性内源RNA潜力
DOI:10.2147/ott.s116392
发表时间:2016
期刊:OncoTargets and therapy
影响因子:4
作者:He HT;Xu M;Kuang Y;Han XY;Wang MQ;Yang Q
通讯作者:Yang Q
MiR-589-5p is a potential prognostic marker of hepatocellular carcinoma and regulates tumor cell growth by targeting MIG-6
MiR-589-5p 是肝细胞癌的潜在预后标志物,通过靶向 MIG-6 调节肿瘤细胞生长
DOI:10.4149/neo_2018_171125n762
发表时间:2018
期刊:Neoplasma
影响因子:3
作者:M Xu;Y Wang;H T He;Q Yang
通讯作者:Q Yang
Cytotoxic effect of oxaloacetate on HepG2-human hepatic carcinoma cells via apoptosis and ROS accumulation
草酰乙酸通过凋亡和ROS积累对HepG2-人肝癌细胞的细胞毒作用
DOI:10.4149/neo_2017_204
发表时间:2017-01-01
期刊:NEOPLASMA
影响因子:3
作者:Jiao, Y.;Ji, L.;Yang, Q.
通讯作者:Yang, Q.
A microRNA expression signature as a predictor of survival for colon adenocarcinoma
microRNA 表达特征作为结肠腺癌生存的预测因子
DOI:10.4149/neo_2017_107
发表时间:2017-01-01
期刊:NEOPLASMA
影响因子:3
作者:Xu, M.;Kuang, Y.;Yang, Q.
通讯作者:Yang, Q.
p53/SNHG1/TAF1调控环路通过PKM2调控细胞糖酵解机制的研究
  • 批准号:
    31972890
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2019
  • 负责人:
    杨青
  • 依托单位:
国内基金
海外基金